Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay.

Soodla P, Simmons R, Huik K, Pauskar M, Jõgeda EL, Rajasaar H, Kallaste E, Maimets M, Avi R, Murphy G, Porter K, Lutsar I; Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord.

HIV Med. 2018 Jan;19(1):33-41. doi: 10.1111/hiv.12535. Epub 2017 Aug 1.

PMID:
28762652
2.

The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients.

Lepeytre F, Cardinal H, Fradette L, Verhave J, Dorais M, LeLorier J, Pichette V, Madore F.

Clin Kidney J. 2017 Jun;10(3):375-380. doi: 10.1093/ckj/sfw144. Epub 2017 Feb 18.

3.

The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C.

van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland SA, Marshall A, Saeed S, Wilson J, Klein MB, Sagan SM.

Can J Gastroenterol Hepatol. 2016;2016:7603526. Epub 2016 Oct 24.

4.

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future.

Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.

Euro Surveill. 2016;21(10):30162. doi: 10.2807/1560-7917.ES.2016.21.10.30162.

5.

A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model.

Nakagawa F, van Sighem A, Thiebaut R, Smith C, Ratmann O, Cambiano V, Albert J, Amato-Gauci A, Bezemer D, Campbell C, Commenges D, Donoghoe M, Ford D, Kouyos R, Lodwick R, Lundgren J, Pantazis N, Pharris A, Quinten C, Thorne C, Touloumi G, Delpech V, Phillips A; SSOPHIE project working group in EuroCoord.

Epidemiology. 2016 Mar;27(2):247-56. doi: 10.1097/EDE.0000000000000423. Erratum in: Epidemiology. 2016 May;27(3):e24.

6.

HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013-March 2014.

Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2015 Aug 31;10(8):e0137062. doi: 10.1371/journal.pone.0137062. eCollection 2015.

7.

Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan.

Takebe Y, Naito Y, Raghwani J, Fearnhill E, Sano T, Kusagawa S, Mbisa JL, Zhang H, Matano T, Brown AJ, Pybus OG, Dunn D, Kondo M; UK Collaborative Group on HIV Drug Resistance.

J Virol. 2014 Sep 1;88(17):9864-76. doi: 10.1128/JVI.01354-14. Epub 2014 Jun 18.

8.

Evaluation of rapid progressors in HIV infection as an extreme phenotype.

Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):15-21. doi: 10.1097/QAI.0000000000000240.

9.

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.

Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2014 Jan 28;9(1):e86719. doi: 10.1371/journal.pone.0086719. eCollection 2014.

10.

Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care.

Verhave JC, Troyanov S, Mongeau F, Fradette L, Bouchard J, Awadalla P, Madore F.

Clin J Am Soc Nephrol. 2014 Apr;9(4):713-9. doi: 10.2215/CJN.06550613. Epub 2014 Jan 23.

11.

The increasing genetic diversity of HIV-1 in the UK, 2002-2010.

UK Collaborative Group on HIV Drug Resistance.

AIDS. 2014 Mar 13;28(5):773-80. doi: 10.1097/QAD.0000000000000119.

12.

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database; UK CHIC study.

AIDS. 2013 Sep 10;27(14):2245-53. doi: 10.1097/QAD.0b013e3283636179.

PMID:
24157905
13.

Natural history of HIV-control since seroconversion.

Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord.

AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01.

PMID:
23912979
14.

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.

Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; UK HIV Drug Resistance Database (UKHDRD); UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother. 2013 Oct;68(10):2339-43. doi: 10.1093/jac/dkt199. Epub 2013 May 27.

15.

High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults.

Simmons R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K; CASCADE collaboration in EuroCoord.

AIDS Behav. 2014 Feb;18(2):411-8. doi: 10.1007/s10461-013-0518-9.

PMID:
23686153
16.

Blood pressure changes associated with periodic leg movements during sleep in healthy subjects.

Pennestri MH, Montplaisir J, Fradette L, Lavigne G, Colombo R, Lanfranchi PA.

Sleep Med. 2013 Jun;14(6):555-61. doi: 10.1016/j.sleep.2013.02.005. Epub 2013 May 3.

PMID:
23643655
17.

Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.

Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; CASCADE collaboration in EuroCoord.

Clin Infect Dis. 2013 Mar;56(6):888-97. doi: 10.1093/cid/cis1000. Epub 2012 Dec 7.

PMID:
23223594
18.

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

PMID:
23221982
19.

Risk of tuberculosis following HIV seroconversion in high-income countries.

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord.

Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740. Epub 2012 Oct 31.

20.

Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Antivir Ther. 2012;17(6):1039-48. doi: 10.3851/IMP2312. Epub 2012 Aug 15.

PMID:
22910338

Supplemental Content

Loading ...
Support Center